CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AstraZeneca Pharmaceuticals LP v. Par Pharmaceutical Inc.

1:10-cv-00343

Overview

Case Number 1:10-cv-00343
Filing Date 2010-04-26
Status Terminated
Termination Date 2010-12-15
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Inc. Operating Company

Represented By

5 Attorneys Listed

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Stephen M. Ferguson

Department of Justice

Tel: +1 (302) 577-8906
Fax: +1 (302) 577-6630

Department of Justice, Defensive Litigation Unit

Nicole W. Stafford

Email: nstafford@wsgr.com

Dutch D. Chung

UNDELIVERABLE EMAIL 1/23/12

Daniel G. Brown

Email: daniel.brown@lw.com

Plaintiff

The Brigham and Women's Hospital, Inc. Operating Company

Represented By

2 Attorneys Listed

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

AstraZeneca AB NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

IPR Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

AstraZeneca Pharmaceuticals, LP NPE (Individual / Inventor)

Represented By

10 Attorneys Listed

York M. Faulkner

Email: york.faulkner@finnegan.com

William E. McShane

Email: wmcshane@cblh.com

Nathaniel S. Edwards

Email: nathaniel.edwards@finnegan.com

Mary K. Ferguson

Email: Mary.Ferguson@finnegan.com

Kenneth M. Frankel

Email: kenneth.frankel@finnegan.com

Ford F. Farabow

Email: ford.farabow@finnegan.com

Dana Kathryn Severance

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4329
Fax: +1 (302) 661-7710

1313 North Market Street, Suite 1200

Charles E. Lipsey

Email: charles.lipsey@finnegan.com

Bruce S. Manheim , Jr.

Email: bruce.manheim@ropesgray.com

Mary W. Bourke

Womble Bond Dickinson (US) LLP

Tel: +1 (302) 252-4320

1313 North Market Street, Suite 1200

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 9 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2013-12-09
2:13-cv-03438

MUSC Foundation for Research Development v. AstraZeneca Pharmaceuticals LP

Asserted Patent
Status: SCD
U.S. District Court 2013-07-31
2:13-cv-02078

MUSC Foundation for Research Development v. AstraZeneca Pharmaceuticals LP

Asserted Patent
Status: SCD
U.S. District Court 2011-04-05
2:11-cv-00807

Palmetto Pharmaceuticals LLC v. AstraZeneca Pharmaceuticals LP

Asserted Patent
Status: SCD
U.S. District Court 2010-10-26
1:10-cv-00915

AstraZeneca UK Limited v. Watson Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00341

AstraZeneca Pharmaceuticals LP v. Glenmark Generics Inc. USA

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00345

AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd.

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00342

AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00339

AstraZeneca Pharmaceuticals LP v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2010-04-26
1:10-cv-00344

AstraZeneca Pharmaceuticals LP v. Sandoz Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6858618
Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Filed: 2001-11-16
Issued: 2005-02-22
Expired (Term Ended) +31d PTA
Expires: 2021-12-17
US7030152
Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Filed: 1999-08-31
Issued: 2006-04-18
Expired (Term Ended)
Expires: 2019-08-31

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

19

Dispositive

15

Granted

2

Denied

0

Pending / Review

15

Motions by Category

Procedural / Extension Motion 4 Motion to Dismiss 9 Motion to Dismiss (FRCP 12(b)(6)) 6

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
OPINION regarding Motion to Dismiss. Signed by Judge Robert B. Kugler on 12/15/2010. (dlk) (Entered: 12/15/2010)
Entry #35 • 2010-12-15 Document →
Motion to Dismiss Granted
ORDER granting (13) Motion to Dismiss for Lack of Subject Jurisdiction (CASE CLOSED) in case 1:10-cv-00345-RBK-KW; granting (14) Motion to Dismiss for Lack of S...
Entry #36 • 2010-12-15 Document →
Motion to Dismiss Pending / Under Review
REDACTED VERSION of 31 Reply Brief in Support of Motion to Dismiss by Par Pharmaceutical Inc.. (Ferguson, Stephen) (Entered: 11/15/2010)
Entry #33 • 2010-11-15 Document →
Motion to Dismiss Pending / Under Review
REQUEST for Oral Argument by Par Pharmaceutical Inc. re 13 MOTION to Dismiss. (Ferguson, Stephen) Modified on 11/16/2010 (nms). (Entered: 11/15/2010)
Entry #34 • 2010-11-15 Document →
Motion to Dismiss (FRCP 12(b)(6)) Pending / Under Review
REQUEST for Oral Argument by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc., The Brigham and Women's Hospital, Inc. re 13 MOTION to Di...
Entry #32 • 2010-11-12 Document →
Motion to Dismiss (FRCP 12(b)(6)) Pending / Under Review
SEALED REPLY BRIEF re 13 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter, and MOTION to Dismiss for Failure to State a Claim, filed by Par Ph...
Entry #31 • 2010-11-08 Document →

Docket Entries

(68 total)
Pleading / Complaint

COMPLAINT filed against Par Pharmaceutical Inc. - ( Filing fee $ 350, receipt number 0311-725843.) - filed by AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc., AstraZeneca AB. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(els) (Entered: 04/27/2010)

Entry #1 • 2010-04-26
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (els) (Entered: 04/27/2010)

Entry #2 • 2010-04-26
1

Summons Issued as to Par Pharmaceutical Inc. on 4/27/2010. (els)

Entry #3 • 2010-04-26
1
No Actions

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,858,618 B2; 7,030,152 B1; (els) (Entered: 04/27/2010)

Entry #3 • 2010-04-27
1

Disclosure Statement pursuant to Rule 7.1 filed by AstraZeneca AB, AstraZeneca Pharmaceuticals LP, IPR Pharmaceuticals Inc.. (Bourke, Mary) (Entered: 04/28/2010)

Entry #4 • 2010-04-28
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc